CLDN18 and gastric neoplasm: The experience with gastric tumors has shown that the first method (and in particular reporting the actual % of 2 +/3 + positive cells) seems to be more reproducible and with clinical significance, but further evidence for PDAC is needed for choosing the best methodology of CLDN18 scoring and for establishing the threshold for considering a case positive or negative.